Opening soon. Stay in the loop

goodmorrowJoin the opening list

Peptide legal status tracker

What can be prescribed today, what's waiting on the FDA, and what has no lawful route.

Updated Clinical review pending · Educational draft

Every peptide

PeptideWhat people take it forLegal statusAt Goodmorrow
TesamorelinBelly fatFDA-approvedOffered when we open
BremelanotideSexual desireFDA-approvedOffered when we open
GHK-CuSkin and hairCompoundableOffered when we open
SermorelinSleep, recovery and body compositionCompoundableOffered when we open
NAD+EnergyCompoundableOffered when we open
BPC-157Injury and gut repairAwaiting final ruleWaitlist open
TB-500Soft-tissue recoveryAwaiting final ruleWaitlist open
KPVInflammationAwaiting final ruleWaitlist open
MOTS-cMetabolismAwaiting final ruleWaitlist open
SemaxFocusAwaiting final ruleWaitlist open
EpitalonSleep and longevityAwaiting final ruleWaitlist open
Melanotan IITanningAwaiting reviewNot offered
CJC-1295 and ipamorelinGrowth hormoneNo lawful routeWe offer an alternative
Thymosin alpha-1Immune supportNo lawful routeNot offered
AOD-9604Fat lossNo lawful routeWe offer an alternative
DSIPSleepRejectedNot offered
LL-37Off the restricted list in April 2026. FDA review due by February 2027.Awaiting reviewNot offered
DihexaOff the restricted list in April 2026. FDA review due by February 2027.Awaiting reviewNot offered
PEG-MGFOff the restricted list in April 2026. FDA review due by February 2027.Awaiting reviewNot offered
SelankNamed as a candidate to return in early 2026. Not yet reviewed.No lawful routeNot offered

What the labels mean

FDA-approved drug
An approved drug with an FDA label. Can be prescribed, including off-label.
Compoundable now
A licensed pharmacy can compound it for a patient with a prescription.
Backed by FDA advisers, awaiting final rule
FDA advisers voted for it in July 2026. Not compoundable until the FDA publishes a final rule.
Awaiting FDA review
Off the restricted list but not on the allowed one. A review is scheduled before the end of February 2027.
No lawful route today
No lawful compounding route and no scheduled review.
Rejected by FDA advisers
FDA advisers voted against it.

How we got here

  1. September 29, 2023

    The FDA places BPC-157 and roughly 17 other peptides in Category 2, its list of bulk ingredients with significant safety concerns. Licensed pharmacies stop compounding them.

  2. February 27, 2026

    Health Secretary Robert F. Kennedy Jr. says about 14 of the 19 restricted peptides will move back toward compounding.

  3. April 15, 2026

    The FDA announces that nominations for 12 peptides were withdrawn, removing them from Category 2 effective April 22. Removal doesn't make them compoundable; it leaves them on neither list.

  4. May 14, 2026

    Non-injectable GHK-Cu, including topical forms, returns to Category 1 after its nominator clarifies it meant to withdraw only the injectable nomination.

  5. July 23, 2026

    FDA advisers vote 8 to 6 to recommend BPC-157, KPV and TB-500, and 7 to 5 for MOTS-c, overruling the FDA's own scientists.

  6. July 24, 2026

    Advisers back epitalon 7 to 4 and Semax 8 to 5, and reject DSIP (emideltide) 7 to 6.

  7. Next

    The FDA must publish a final rule before pharmacies can compound the six recommended peptides. A second review, due before the end of February 2027, covers injectable GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF.

Hear when the FDA acts

One text when the rule is final and we can prescribe. Nothing else.

What are you interested in?

We'll only use this to contact you about appointments, by phone, text or email. No health details needed here. See our privacy policy.

Questions people ask

Is BPC-157 legal now?

Not for compounding. The July 2026 vote was a recommendation. Until the FDA finalizes it, licensed pharmacies can't make BPC-157 for patients.

What does Category 1 mean?

It's the FDA's interim list of bulk ingredients that pharmacies can compound with while the agency evaluates them. Category 2 is the list flagged for significant safety concerns. A peptide on neither list can't be compounded under the usual rules.

Is a PCAC recommendation the same as FDA approval?

No. The Pharmacy Compounding Advisory Committee advises the FDA, which isn't bound by its votes. Even after a final rule, a compoundable peptide isn't an FDA-approved drug.

How often is this page updated?

Whenever the FDA acts. The date at the top is the last time we checked every entry.

Sources

  1. Secondary sourceFDA Peptide Update 2026: Removal from the Do Not Compound List Frier Levitt, August 2026
  2. Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026
  3. FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
  4. Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
  5. Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
  6. Secondary sourceFDA advisory committee nominates six peptides for pharmacies to compound National Community Pharmacists Association, July 31, 2026
  7. Secondary sourceBulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, July 28, 2026
  8. Secondary sourceThe US Peptide Status Index Peptide America

Good days ahead.

Join the opening list for appointment updates.

Join the opening list